1536P - Multicenter institutional experience of surgically resected thymic epithelial tumors (TETs): an observational report on behalf of F.O.N.I.C.A.P. (Fo...

Date 30 September 2012
Event ESMO Congress 2012
Session Poster presentation II
Topics Thymoma and Thymic Cancer
Surgery and/or Radiotherapy of Cancer
Presenter Giovenzio Genestreti
Authors G. Genestreti1, M.A. Burgio1, L. Ampollini2, S. Sanna3, M. Monti1, A. Santo4, M. Mezzetti5, G. Gavelli6, A. Verlicchi7, R. Buosi8
  • 1Medical Oncology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, 47014 - Meldola (FC)/IT
  • 2Department Of Thoracic Surgery, University Hospital, Parma, Italy, Parma/IT
  • 3Department Of Thoracic Surgery, Morgagni-Pierantoni Hospital, Forlì, Italy, Forlì/IT
  • 4Department Of Medical Oncology, University Hospital, Verona, Italy, Verona/IT
  • 5Department Of Thoracic Surgery, San Carlo Clinic, Milan, Italy, Milan/IT
  • 6Department Of Radiology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola (FC)/IT
  • 7Dipartimento Di Oncologia/ematologia, Ospedale Civile di Ravenna - S.ta Maria delle Croci, IT-48121 - Ravenna/IT
  • 8Department Of Clinical Oncology, Civil Hospital, Novara, Italy, Novara/IT



thymic epithelial tumors (TETs) are a rare neoplasms. Due to their rarity, large-scale prospective trials are lacking. The present retrospective multicenter analysis aimed to evaluate clinical outcome and clinical-pathological features of TETs after complete surgical resection and adjuvant treatments (Adj) such as chemotherapy (CHT) or radiotherapy (RT).

Patients and methods

Patients who underwent a complete surgical resections for TETs between 2000 and 2007 were reviewed. WHO histological classification criteria and Masaoka staging system were used. Adj were: anthracycline- and platin-based CHT, RT on irradiation fields covering the primary tumor bed. Overall survival (OS) was calculated from the date of diagnosis until patient death or last follow-up visit. Disease free-survival (DFS) was defined as the interval between surgery and date of first documentation of recurrence. OS, DFS and 95% Confidence Interval (95% CI) were estimated by Kaplan-Meier method.


62 patients were analyzed: 30 patients (48%) male and 32 (52%) female. Median age was 60 years (range: 33 - 86). At the beginning of their cancer history 20 (32%) patients had myasthenia. Clinical staging showed: 31 (50%) stage I disease, 19 (30%) stage II, 5 (8%) stage III, 2 (4%) stage IVa, 5 (8%) stage IVb. Histologies were: 11 (19%) A tumor type, 18 (29%) AB type, 7 (12%) B1 type, 11 (17%) B2 type, 11 (17%) B3 type and 3 (6%) C type. Pathological staging were: 30 (48%) stage I, 22 (35%) stage II, 3 (6%) stage III, 2 (3%) stage IVa, 5 (8%) stage IVb. 3 (5%) patients received Adj-CHT and 16 (26%) Adj-RT. Median follow-up was 71 months (range 1-145), DFS and OS are the following:

% DFS (95% CI) % OS (95% CI)
Events 48 mo 60 o0 72 mo Events 48 mo 60 mo 72 mo
9 89 (80-97) 89 (80-97) 86 (76-96) 7 97 (92-100) 95 (88-100) 92 (85-100)

mo, months.


TETs are rare and indolent tumors. Surgery offers good results which can be further improved by Adj such as CHT and/or RT. Supported by GIPO.


All authors have declared no conflicts of interest.